Sugi Predict

Sugi Predict / Compounds / SCHEMBL1991028

SCHEMBL1991028

SCHEMBL1991028

NC(=O)Cc1nc(Cl)nc2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 2/20 0.45
▸ ACACA Q13085 2/20 0.44
▸ BCHE P06276 1/20 0.43
▸ PDE10A Q9Y233 1/20 0.42
▸ APP P05067 2/20 0.42
▸ PDE5A O76074 1/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ GLA P06280 1/20 0.41
▸ PRNP P04156 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ RAD52 P43351 1/20 0.40
▸ MAOA P21397 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ GRM2 Q14416 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ GBA1 P04062 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27392577 0.81 PRNP (0.48) ACHEACACABCHEPDE10AKDM4E
SCHEMBL13502532 0.79 PRNP (0.59) ACACAPDE10APDE5AKDM4EPRNP
SCHEMBL31647297 0.78 ALDH1A1 (0.51) KDM4EGLAPRNPSMN1; SMN2POLB
SCHEMBL3937592 0.78 APP (0.47) ACHEAPPPDE5AKDM4EGLA
SCHEMBL2998020 0.74 KDM4E (0.50) ACHEACACABCHEKDM4EPOLB
SCHEMBL2990475 0.74 ADORA3 (0.42) ACHEACACAKDM4EGLASMN1; SMN2
SCHEMBL31434291 0.73 MEN1 (0.45) ACHEACACABCHEPDE10AKDM4E
SCHEMBL4904315 0.72 APP (0.44) ACHEAPPPDE5AKDM4EGLA
SCHEMBL1993273 0.72 ADORA2A (0.43) SMN1; SMN2POLBALDH1A1KMT2A
Bicarbonate SCHEMBL11023181 0.72 MAOA (0.48) PDE10AAPPPDE5AKDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025136129-A1 TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET PROTEIN KINASE C CAPTOR THERAPEUTICS S.A. (PL) 2025-06-26 — — WO disclosed
WO-2013004709-A1 INDOLYLMALEIMIDES AS SOFT PAN-PKC INHIBITORS AMAKEM NV (BE) 2013-01-10 — — WO disclosed
WO-2011079105-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 — — WO disclosed
WO-2011079105-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 — — WO disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 — — US disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 — — US disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 — — US disclosed
US-7825124-B2 Indolylmaleimide derivatives ALBERT RAINER 2010-11-02 — — US disclosed
US-7786123-B2 Indolylmaleimide derivatives ALBERT RAINER 2010-08-31 — — US disclosed
US-20090318463-A1 Indolylmaleimide Derivatives ALBERT RAINER 2009-12-24 — — US disclosed
EP-2070921-A1 Indolylmaleimide derivatives as protein kinase c inhibitors Novartis Ag (CH) 2009-06-17 — — EP disclosed
US-20070191401-A1 Transplant rejection, autoimmune disease, autoimmune disease ALBERT RAINER 2007-08-16 — — US disclosed
US-20070184061-A1 Indolylmaleimide derivatives ALBERT RAINER 2007-08-09 — — US disclosed
US-20070155817-A1 Indolylmaleimide derivatives ALBERT RAINER 2007-07-05 — — US disclosed
US-7220774-B2 Indolylmaleimide derivatives NOVARTIS AG (CH) 2007-05-22 — — US disclosed
US-20040053949-A1 Indolylmaleimide derivatives ALBERT RAINER (CH) 2004-03-18 — — US disclosed
US-6645970-B2 Preventing T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer NOVARTIS AG (CH) 2003-11-11 — — US disclosed
EP-1337527-A1 INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS Novartis AG (CH) 2003-08-27 — — EP disclosed
US-20030069424-A1 Indolylmaleimide derivatives NOVARTIS AG (CH) 2003-04-10 — — US disclosed
WO-2002038561-A1 INDOLYLMALEIMIDE DERIVATIVES AS PROTEIN KINASE C INHIBITORS NOVARTIS AG (CH) 2002-05-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318463-A1 Indolylmaleimide Derivatives NFATC1, INMT, IDO1 ACHE 2973/4885ACACA 1263/4885BCHE 799/4885
US-20070191401-A1 Transplant rejection, autoimmune disease, autoimmune disease NFATC1, HLA-DRB1, INMT ACHE 3914/4885ACACA 1984/4885BCHE 1190/4885
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS TPMT, TSLP, THPO ACHE 4127/4885ACACA 4739/4885BCHE 4442/4885
US-20030069424-A1 Indolylmaleimide derivatives NFATC1, INMT, IDO1 ACHE 2973/4885ACACA 1263/4885BCHE 799/4885
US-20040053949-A1 Indolylmaleimide derivatives NFATC1, INMT, IDO1 ACHE 2973/4885ACACA 1263/4885BCHE 799/4885
US-20070155817-A1 Indolylmaleimide derivatives NFATC1, INMT, IDO1 ACHE 2973/4885ACACA 1263/4885BCHE 799/4885
US-20070184061-A1 Indolylmaleimide derivatives NFATC1, INMT, IDO1 ACHE 2973/4885ACACA 1263/4885BCHE 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.